Gilead Sciences Inc (GILD)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$150.93+$1.24 (+0.83%) on the dayAs of the close; data may be delayed.
GILD price, last 12 months
Key stats
- Previous close
- $149.69
- Open
- $150.05
- Day range
- $148.02 – $151.00
- 52-week range
- $108.46 – $157.29
- Volume
- 5.3M
- Avg volume (20 days)
- 5.9M
- Market cap
- $187.1B
Performance
1W+0.6%
1M+1.9%
3M+18.0%
6M+10.3%
YTD+23.0%
1Y+32.8%
vs S&P 500, 1Y+16.0 pts
Technicals and fundamentals
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $187.1B